Sections
Gastroenterology
Biography
Alan Moss, MD, FACG, AGAF, FEBG, FRCPI is a clinician-scientist with an interest in Crohn's disease and Ulcerative Colitis (Inflammatory Bowel Disease, IBD). His clinical expertise is in management of IBD, and he is Director of the Crohn's & Colitis Program at Boston Medical Center. His research interests include microbial therapeutics, mucosal immunology and clinical outcomes. He has held grant funding from NIDDK, AGA, Helmsley Charitable Trust, and the Crohn's & Colitis Foundation. He has published over 120 research papers (h-index 28), including many cited in national and international practice guidelines. Dr Moss has held positions as Deputy-Editor of Crohn's & Colitis 360, and as Associate Editor for Journal of Crohn’s & Colitis (ECCO), Frontline Gastroenterology (BMJ) and the World Journal of Gastroenterology. He has served on the Nominating Committee of the IBD section of AGA, and the Professional Education and National Scientific Advisory Committee for the Crohn's & Colitis Foundation. He is a reviewer for national and international research bodies, including the NIDDK and European Research Council.
Publications
Kohli A, Moss AC. Personalizing therapy selection in inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Apr; 19(4):431-438. PMID: 37051666.
Published on 9/23/2022Tandon K, Moss AC. Let thy food be thy medicine. Frontline Gastroenterol. 2023; 14(1):3. PMID: 36561786.
Published on 6/1/2022Moss AC. Approach to Treatment Failure in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2022 Jun; 18(6):360-363. PMID: 36398141.
Published on 12/1/2021Goldowsky A, Singh R, Charabaty A, Moss AC. P033 Moving the Needle on Speaker Diversity at AIBD. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S8. PMID: 35006161.
Published on 10/18/2021Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, Abraham B, Hudesman D, Malter L, McCabe R, Holubar S, Afzali A, Cheifetz AS, Gaidos JKJ, Moss AC. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 10 18; 27(10):1552-1563. PMID: 34279600.
Published on 6/9/2021Ayyar KK, Moss AC. Exosomes in Intestinal Inflammation. Front Pharmacol. 2021; 12:658505. PMID: 34177577.
Published on 1/19/2021Osterman MT, Scott FI, Fogt FF, Gilroy ED, Parrott S, Galanko J, Cross R, Moss A, Herfarth HH, Higgins PDR. Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). Inflamm Bowel Dis. 2021 01 19; 27(2):207-214. PMID: 32170946.
Published on 11/18/2020Harshe RP, Xie A, Vuerich M, Frank LA, Gromova B, Zhang H, Robles RJ, Mukherjee S, Csizmadia E, Kokkotou E, Cheifetz AS, Moss AC, Kota SK, Robson SC, Longhi MS. Endogenous antisense RNA curbs CD39 expression in Crohn's disease. Nat Commun. 2020 11 18; 11(1):5894. PMID: 33208731.
Published on 10/12/2020Donet JA, Charabaty A, Moss AC. Management of Asymptomatic Terminal Ileitis. Crohns Colitis 360. 2020 Oct; 2(4):otaa065. PMID: 36777745.
Published on 9/25/2020Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am. 2020 12; 49(4):689-704. PMID: 33121689.
Media Mentions
Published on 1/30/2023
VIDEO: Point-of-care, drug-level assays help predict ‘best time, best dose’ in IBD therapy
Published on 7/11/2022
Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study
Published on 6/27/2020
Biosimilars Face High Expectations, But Also Barriers to Acceptance
View full list of 3 media mentions.